Cardiovascular RNA interference therapy: The broadening tool and target spectrum

Circulation Research

Volumn 113, Issue 5, 2013, Pages 588-602

  Poller, Wolfgang ^a   Tank, Juliane ^a   Skurk, Carsten ^a   Gast, Martina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cardiovascular diseases; genetic therapy; immunity, innate; nanoparticles; RNA interference; RNA, long untranslated; RNA, short untranslated

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOPHILIN D; DOUBLE STRANDED RNA; LONG UNTRANSLATED RNA; MALATE DEHYDROGENASE (DECARBOXYLATING); MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIN; PIWI INTERACTING RNA; RECOMBINANT SOMATOMEDIN C; RNA; RNA BINDING PROTEIN; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL NUCLEAR RNA; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNTRANSLATED RNA; ZINC FINGER NUCLEASE;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; DNA RNA HYBRIDIZATION; EMBRYONIC STEM CELL; EVOLUTIONARY ADAPTATION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC ASSOCIATION; GENETIC CODE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN GENOME; IN VITRO STUDY; LONG QT SYNDROME; NONHUMAN; PHENOTYPE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN RNA BINDING; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; RNA STRUCTURE; STEM CELL TRANSPLANTATION; STRESS; VIRUS INFECTION;

CARDIOVASCULAR DISEASES; GENETIC THERAPY; IMMUNITY, INNATE; NANOPARTICLES; RNA INTERFERENCE; RNA, LONG UNTRANSLATED; RNA, SHORT UNTRANSLATED;

ANIMALS; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FORECASTING; GENETIC THERAPY; GENETIC VECTORS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; SUBSTRATE SPECIFICITY; TRANSCRIPTOME; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883313004     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301056     Document Type: Review

References (149)

1. Mattick JS, Taft RJ, Faulkner GJ. A global view of genomic information- moving beyond the gene and the master regulator. Trends Genet. 2010;26:21-28
2. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74
3. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241-1252
4. Majmudar MD, Keliher EJ, Heidt T, et al. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation. 2013;127:2038-2046
5. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res. 2012;110:496-507
6. Abdellatif M. Differential expression of microRNAs in different disease states. Circ Res. 2012;110:638-650
7. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508-522
8. Boettger T, Braun T. A new level of complexity: The role of microRNAs in cardiovascular development. Circ Res. 2012;110:1000-1013
9. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013;33:206-214
10. Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, Vandesompele J, Mestdagh P. LNCipedia: A database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41:D246-D251
11. Sun J, Gao B, Zhou M, Wang ZZ, Zhang F, Deng JE, Li X. Comparative genomic analysis reveals evolutionary characteristics and patterns of microRNA clusters in vertebrates. Gene. 2013;512:383-391
12. Wang QH, Zhou M, Sun J, Ning SW, Li Y, Chen L, Zheng Y, Li X, Lv SL, Li X. Systematic analysis of human microRNA divergence based on evolutionary emergence. FEBS Lett. 2011;585:240-248
13. Meunier J, Lemoine F, Soumillon M, Liechti A, Weier M, Guschanski K, Hu H, Khaitovich P, Kaessmann H. Birth and expression evolution of mammalian microRNA genes. Genome Res. 2013;23:34-45
14. Hertel J, Bartschat S, Wintsche A, Otto C, Stadler PF; Students of the Bioinformatics Computer Lab. Evolution of the let-7 microRNA family. RNA Biol. 2012;9:231-241
15. Zhang X, Rossi JJ. Phylogenetic comparison of small RNA-triggered transcriptional gene silencing. J Biol Chem. 2011;286:29443-29448
16. Sun J, Zhou M, Mao ZT, Hao DP, Wang ZZ, Li CX. Systematic analysis of genomic organization and structure of long non-coding RNAs in the human genome. FEBS Lett. 2013;587:976-982
17. Wheeler BM, Heimberg AM, Moy VN, Sperling EA, Holstein TW, Heber S, Peterson KJ. The deep evolution of metazoan microRNAs. Evol Dev. 2009;11:50-68
18. Heimberg AM, Sempere LF, Moy VN, Donoghue PC, Peterson KJ. MicroRNAs and the advent of vertebrate morphological complexity. Proc Natl Acad Sci U S A. 2008;105:2946-2950
19. Kung JT, Lee JT. RNA in the loop. Dev Cell. 2013;24:565-567
20. Clark MB, Amaral PP, Schlesinger FJ, et al. The reality of pervasive transcription. PLoS Biol. 2011;9:e1000625; discussion e1001102
21. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 2011;146:353-358
22. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP. Codingindependent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147:344-357
23. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033-1038
24. Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, Zhang Q, Yan G, Cui Q. LncRNADisease: A database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41:D983-D986
25. Yang JH, Li JH, Jiang S, Zhou H, Qu LH. ChIPBase: A database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res. 2013;41:D177-D187
26. Martin JA, Wang Z. Next-generation transcriptome assembly. Nat Rev Genet. 2011;12:671-682
27. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11:31-46
28. Ozsolak F, Milos PM. RNA sequencing: Advances, challenges and opportunities. Nat Rev Genet. 2011;12:87-98
29. Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y, Xiao X. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res. 2011;109:1332-1341
30. Song HK, Hong SE, Kim T, Kim do H. Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLoS One. 2012;7:e35552
31. Wan Y, Kertesz M, Spitale RC, Segal E, Chang HY. Understanding the transcriptome through RNA structure. Nat Rev Genet. 2011;12:641-655
32. Wilusz JE, Freier SM, Spector DL. 3' end processing of a long nuclearretained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135:919-932
33. Naganuma T, Nakagawa S, Tanigawa A, Sasaki YF, Goshima N, Hirose T. Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. EMBO J. 2012;31:4020-4034
34. Naganuma T, Hirose T. Paraspeckle formation during the biogenesis of lncRNAs. RNA Biol. 2013;10:456-461
35. Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R. Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev. 2008;22:2773-2785
36. Wee LM, Flores-Jasso CF, Salomon WE, Zamore PD. Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell. 2012;151:1055-1067
37. De N, Young L, Lau PW, Meisner NC, Morrissey DV, MacRae IJ. Highly complementary target RNAs promote release of guide RNAs from human Argonaute2. Mol Cell. 2013;50:344-355
38. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, Dorrestein PC, Rosenfeld MG. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell. 2011;147:773-788
39. Souquere S, Beauclair G, Harper F, Fox A, Pierron G. Highly ordered spatial organization of the structural long noncoding NEAT1 RNAs within paraspeckle nuclear bodies. Mol Biol Cell. 2010;21:4020-4027
40. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-166
41. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338:1435-1439
42. Ip JY, Nakagawa S. Long non-coding RNAs in nuclear bodies. Dev Growth Differ. 2012;54:44-54
43. Kay MA. State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet. 2011;12:316-328
44. Goonasekera SA, Lam CK, Millay DP, Sargent MA, Hajjar RJ, Kranias EG, Molkentin JD. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest. 2011;121:1044-1052
45. Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876-885
46. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537-541
47. Eckstein A, Grössl T, Geisler A, Wang X, Pinkert S, Pozzuto T, Schwer C, Kurreck J, Weger S, Vetter R, Poller W, Fechner H. Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antiviral Res. 2010;88:86-94
48. Fechner H, Sipo I, Westermann D, Pinkert S, Wang X, Suckau L, Kurreck J, Zeichhardt H, Müller O, Vetter R, Erdmann V, Tschope C, Poller W. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med (Berl). 2008;86:987-997
49. Werk D, Pinkert S, Heim A, Zeichhardt H, Grunert HP, Poller W, Erdmann VA, Fechner H, Kurreck J. Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Res. 2009;83:298-306
50. Fechner H, Pinkert S, Wang X, Sipo I, Suckau L, Kurreck J, Dörner A, Sollerbrant K, Zeichhardt H, Grunert HP, Vetter R, Schultheiss HP, Poller W. Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther. 2007;14:960-971
51. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest. 2013;123:53-61
52. Lompré AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation. 2010;121:822-830
53. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313
54. Lipskaia L, Chemaly ER, Hadri L, Lompre AM, Hajjar RJ. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther. 2010;10:29-41
55. Poller W, Hajjar R, Schultheiss HP, Fechner H. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res. 2010;86:353-364
56. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat Rev Genet. 2011;12:341-355
57. Pinkert S, Westermann D, Wang X, et al. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation. 2009;120:2358-2366
58. Castanotto D, Rossi JJ. The promises and pitfalls of RNA- interferencebased therapeutics. Nature. 2009;457:426-433
59. Huang M, Wu JC. Molecular imaging of RNA interference therapy targeting PHD2 for treatment of myocardial ischemia. Methods Mol Biol. 2011;709:211-221
60. Wang WE, Yang D, Li L, Wang W, Peng Y, Chen C, Peng C, Xia X, Wang H, Jiang J, Liao Q, Li Y, Xie G, Huang H, Guo Y, et al. Phd2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. Circ Res. 2013;113:288-300. doi: 10.1161/CIRCRESAHA.113. 300929
61. Matsa E, Dixon JE, Medway C, Georgiou O, Patel MJ, Morgan K, Kemp PJ, Staniforth A, Mellor I, Denning C. Allele-specific RNAi rescues the long-qt syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J. March 6, 2013. doi: 10.1093/eurheartj/eht067. http:// eurheartj.oxfordjournals.org/content/early/2013/03/06/eurheartj.eht067. long. Accessed August 2, 2013
62. Zhang X, Beduhn M, Zheng X, Lian D, Chen D, Li R, Siu LK, Marleau A, French PW, Ichim TE, Min WP. Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors. Am J Transplant. 2012;12:2675-2688
63. Ramachandran PV, Ignacimuthu S. RNA interference-a silent but an efficient therapeutic tool. Appl Biochem Biotechnol. 2013;169:1774-1789
64. Gupta S, Maitra R, Young D, Gupta A, Sen S. Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2009;297:H627-H636
65. Torrado M, Iglesias R, Centeno A, López E, Mikhailov AT. Targeted genesilencing reveals the functional significance of myocardin signaling in the failing heart. PLoS One. 2011;6:e26392
66. Lin HH, Chen YH, Chiang MT, Huang PL, Chau LY. Activator protein-2a mediates carbon monoxide-induced stromal cell-derived factor-1a expression and vascularization in ischemic heart. Arterioscler Thromb Vasc Biol. 2013;33:785-794
67. Maddaford TG, Dibrov E, Hurtado C, Pierce GN. Reduced expression of the Na+/Ca2+ exchanger in adult cardiomyocytes via adenovirally delivered shRNA results in resistance to simulated ischemic injury. Am J Physiol Heart Circ Physiol. 2010;298:H360-H366
68. O'Donnell JM, Kalichira A, Bi J, Lewandowski ED. In vivo, cardiacspecific knockdown of a target protein, malic enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA. Curr Gene Ther. 2012;12:454-462
69. Kato M, Akao M, Matsumoto-Ida M, Makiyama T, Iguchi M, Takeda T, Shimizu S, Kita T. The targeting of cyclophilin D by RNAi as a novel cardioprotective therapy: Evidence from two-photon imaging. Cardiovasc Res. 2009;83:335-344
70. Guo T, Wang J, Yang J, Chen W, An G, Fan L, Peng Q. Lentivirusmediated RNAi of chymase increases the plaque stability in atherosclerosis in vivo [published online ahead of print May 24, 2013]. Exp Mol Pathol. 2013;95:51-56. doi: 10.1016/j.yexmp.2013.05.005
71. Holley CL, Topkara VK. An introduction to small non-coding RNAs: MiRNA and snoRNA. Cardiovasc Drugs Ther. 2011;25:151-159
72. Davidson BL, McCray PB Jr. Current prospects for RNA interferencebased therapies. Nat Rev Genet. 2011;12:329-340
73. Lennox KA, Behlke MA. A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res. 2010;27:1788-1799
74. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011;43:371-378
75. Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R, Corradini R. Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol. 2011;82:1416-1429
76. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A. Generation of miRNA sponge constructs. Methods. 2012;58:113-117
77. Poller W, Fechner H. Development of novel cardiovascular therapeutics from small regulatory RNA molecules-an outline of key requirements. Curr Pharm Des. 2010;16:2252-2268
78. Nakai H, Thomas CE, Storm TA, Fuess S, Powell S, Wright JF, Kay MA. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol. 2002;76:11343-11349
79. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:11854-11859
80. Gao GP, Lu Y, Sun X, Johnston J, Calcedo R, Grant R, Wilson JM. Highlevel transgene expression in nonhuman primate liver with novel adenoassociated virus serotypes containing self-complementary genomes. J Virol. 2006;80:6192-6194
81. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-inhuman phase . clinical trial. J Card Fail. 2009;15:171-181
82. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM, Sweeney HL. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008;19:1359-1368
83. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006;14:45-53
84. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolotukhin I, Tarantal AF, Byrne BJ. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006;99:e3-e9
85. Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, Fechner H, Müller OJ. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 2011;18:199-209
86. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, Pu D, Hu X, Wang DZ, Li J, Xiao X. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A. 2009;106:3946-3951
87. Okada H, Ishibashi H, Hayashita-Kinoh H, Chiyo T, Nitahara-Kasahara Y, Baba Y, Watanabe S, Takeda S, Okada T. Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9. Mol Ther Nucleic Acids. 2013;2:e95
88. Goehringer C, Rutschow D, Bauer R, Schinkel S, Weichenhan D, Bekeredjian R, Straub V, Kleinschmidt JA, Katus HA, Müller OJ. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res. 2009;82:404-410
89. Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res. 2006;70:70-78
90. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9:1327-1333
91. Liu YP, Haasnoot J, ter Brake O, Berkhout B, Konstantinova P. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res. 2008;36:2811-2824
92. Lau S, Graham B, Cao N, Boyd BJ, Pouton CW, White PJ. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNAalbumin conjugation. Mol Pharm. 2012;9:71-80
93. Lu P, Yuan L, Wang Y, Du Q, Sheng J. Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol. 2012;5:698-706
94. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010;1:4
95. Nolte A, Walker T, Schneider M, Kray O, Avci-Adali M, Ziemer G, Wendel HP. Small-interfering RNA-eluting surfaces as a novel concept for intravascular local gene silencing. Mol Med. 2011;17:1213-1222
96. Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther. 2012;20:73-83
97. Sioud M. Recent advances in small interfering RNA sensing by the immune system. N Biotechnol. 2010;27:236-242
98. Toroney R, Hull CM, Sokoloski JE, Bevilacqua PC. Mechanistic characterization of the 5'-triphosphate-dependent activation of PKR: Lack of 5'-end nucleobase specificity, evidence for a distinct triphosphate binding site, and a critical role for the dsRBD. RNA. 2012;18:1862-1874
99. Mao CP, Wu TC. Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol Biol. 2010;623:325-339
100. Büning H. Gene therapy enters the pharma market: The short story of a long journey. EMBO Mol Med. 2013;5:1-3
101. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB, Boyer LA. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell. 2013;152:570-583
102. Castel SE, Martienssen RA. RNA interference in the nucleus: Roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet. 2013;14:100-112
103. Kemp C, Mueller S, Goto A, Barbier V, Paro S, Bonnay F, Dostert C, Troxler L, Hetru C, Meignin C, Pfeffer S, Hoffmann JA, Imler JL. Broad RNA interference-mediated antiviral immunity and virus-specific inducible responses in Drosophila. J Immunol. 2013;190:650-658
104. Parameswaran P, Sklan E, Wilkins C, et al. Six RNA viruses and fortyone hosts: Viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog. 2010;6:e1000764
105. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet. 2011;12:846-860
106. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99-110
107. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492:376-381
108. Mercola M. Cardiovascular biology: A boost for heart regeneration. Nature. 2012;492:360-362
109. Pasquinelli AE. MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13:271-282
110. Roberts CT Jr, Kurre P. Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication. Cancer Res. 2013;73:3200-3205
111. Ohanian M, Humphreys DT, Anderson E, Preiss T, Fatkin D. A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. BMC Genet. 2013;14:18
112. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the mir155 host gene in physiological and pathological processes. Gene. 2012;112:01512-0
113. Sati S, Ghosh S, Jain V, Scaria V, Sengupta S. Genome-wide analysis reveals distinct patterns of epigenetic features in long non-coding RNA loci. Nucleic Acids Res. 2012;40:10018-10031
114. Peng X, Gralinski L, Armour CD, et al. Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio. 2010;1:e00206-e00210
115. Tsitsiou E, Williams AE, Moschos SA, Patel K, Rossios C, Jiang X, Adams OD, Macedo P, Booton R, Gibeon D, Chung KF, Lindsay MA. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J Allergy Clin Immunol. 2012;129:95-103
116. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477:295-300
117. Schonrock N, Harvey RP, Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res. 2012;111:1349-1362
118. Marian AJ, Belmont J. Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res. 2011;108:1252-1269
119. Johnson AD, Hwang SJ, Voorman A, et al. Resequencing and clinical associations of the 9p21.3 region: A comprehensive investigation in the Framingham heart study. Circulation. 2013;127:799-810
120. Congrains A, Kamide K, Oguro R, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis. 2012;220:449-455
121. Pasmant E, Sabbagh A, Vidaud M, Bièche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011;25:444-448
122. Congrains A, Kamide K, Katsuya T, Yasuda O, Oguro R, Yamamoto K, Ohishi M, Rakugi H. CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun. 2012;419:612-616
123. Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: Molecular Mechanisms and Implications in Human Health. Int J Mol Sci. 2013;14:1278-1292
124. Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, Lu X. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal. 2013;25:1086-1095
125. Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A, Miyamoto Y, Ikegawa S, Kamatani N, Hori M, Saito S, Nakamura Y, Tanaka T. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51:1087-1099
126. Tsuiji H, Yoshimoto R, Hasegawa Y, Furuno M, Yoshida M, Nakagawa S. Competition between a noncoding exon and introns: Gomafu contains tandem UACUAAC repeats and associates with splicing factor-1. Genes Cells. 2011;16:479-490
127. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007;8:39
128. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev. 2009;23:1494-1504
129. Eismann M, Gutschner T, Hämmerle M, Günther S, Caudron-Herger M, Gros M, Schirmacher P, Rippe K, Braun T, Zörnig M, Diederichs S. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol. 2012;9:1076-1087
130. Gutschner T, Baas M, Diederichs S. Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res. 2011;21:1944-1954
131. Nakagawa S, Ip JY, Shioi G, Tripathi V, Zong X, Hirose T, Prasanth KV. Malat1 is not an essential component of nuclear speckles in mice. RNA. 2012;18:1487-1499
132. Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, Xiao X, Booth CJ, Wu J, Zhang C, Spector DL. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2:111-123
133. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180-1189
134. Pichlmair A, Lassnig C, Eberle CA, Górna MW, Baumann CL, Burkard TR, Bürckstümmer T, Stefanovic A, Krieger S, Bennett KL, Rülicke T, Weber F, Colinge J, Müller M, Superti-Furga G. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol. 2011;12:624-630
135. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol. 2011;85:12881-12889
136. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol. 2012;13:214-222
137. Mao YS, Sunwoo H, Zhang B, Spector DL. Direct visualization of the co-transcriptional assembly of a nuclear body by noncoding RNAs. Nat Cell Biol. 2011;13:95-101
138. Zhang Q, Chen CY, Yedavalli VS, Jeang KT. NEAT1 long noncoding RNA and paraspeckle bodies modulate HIV-1 posttranscriptional expression. MBio. 2013;4:e00596-e00512
139. Geirsson A, Bothwell AL, Hammond GL. Inhibition of alloresponse by a human trophoblast non-coding RNA suppressing class II transactivator promoter III and major histocompatibility class II expression in murine B-lymphocytes. J Heart Lung Transplant. 2004;23:1077-1081
140. Geirsson A, Paliwal I, Lynch RJ, Bothwell AL, Hammond GL. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA. Transplantation. 2003;76:387-394
141. Geirsson A, Lynch RJ, Paliwal I, Bothwell AL, Hammond GL. Human trophoblast noncoding RNA suppresses CIITA promoter III activity in murine B-lymphocytes. Biochem Biophys Res Commun. 2003;301:718-724
142. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, Dinger ME, Mattick JS. Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012;22:885-898
143. Blattmann P, Schuberth C, Pepperkok R, Runz H. RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function. PLoS Genet. 2013;9:e1003338
144. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: A networkbased approach to human disease. Nat Rev Genet. 2011;12:56-68
145. Danchin É, Charmantier A, Champagne FA, Mesoudi A, Pujol B, Blanchet S. Beyond DNA: Integrating inclusive inheritance into an extended theory of evolution. Nat Rev Genet. 2011;12:475-486
146. Lehman N. RNA in evolution. Wiley Interdiscip Rev RNA. 2010;1:202-213
147. Shabalina SA, Koonin EV. Origins and evolution of eukaryotic RNA interference. Trends Ecol Evol. 2008;23:578-587
148. Koonin EV, Senkevich TG, Dolja VV. The ancient Virus World and evolution of cells. Biol Direct. 2006;1:29
149. Mukherjee K, Campos H, Kolaczkowski B. Evolution of animal and plant dicers: Early parallel duplications and recurrent adaptation of antiviral RNA binding in plants. Mol Biol Evol. 2013;30:627-641